Two peptides commonly studied together for their interaction with growth hormone pathways. Here is what the research says and what legal access looks like in Australia.
This article is for general educational purposes only and does not constitute medical advice. CJC-1295 and Ipamorelin are prescription-only medicines in Australia. Access requires assessment and prescription from an AHPRA-registered medical practitioner. Always consult a qualified doctor before making any decisions about your health.
A synthetic analogue of growth hormone releasing hormone. Studied for its interaction with GHRH receptors and influence on growth hormone signalling.
A selective growth hormone secretagogue. Studied for its ability to stimulate growth hormone release through a different receptor pathway to CJC-1295.
Both are Schedule 4 prescription-only medicines in Australia. Require a valid prescription from an AHPRA-registered doctor.
CJC-1295 is a synthetic peptide analogue of growth hormone releasing hormone, commonly referred to as GHRH. GHRH is a hormone naturally produced by the hypothalamus that signals the pituitary gland to release growth hormone. CJC-1295 is designed to interact with the same GHRH receptors, mimicking and extending this signalling process.
A key characteristic of CJC-1295 that distinguishes it from earlier GHRH analogues is its extended half-life. Earlier GHRH analogues were rapidly broken down in the body, limiting their research utility. CJC-1295 was designed to resist this degradation, allowing it to remain active for longer.
CJC-1295 is available in two forms. One version includes what is referred to as Drug Affinity Complex, or DAC, which binds to albumin in the blood and further extends the compound's active duration significantly. The other version without DAC has a shorter active window. The prescribing doctor determines which form is appropriate for an individual based on their specific circumstances and protocol.
Ipamorelin is a selective growth hormone secretagogue, meaning it stimulates the release of growth hormone from the pituitary gland. Unlike CJC-1295, which works through the GHRH receptor pathway, Ipamorelin works through a different receptor called the ghrelin receptor, also known as the growth hormone secretagogue receptor.
What has made Ipamorelin of particular research interest is its selectivity. Earlier growth hormone secretagogues were associated with stimulating the release of other hormones alongside growth hormone, including cortisol and prolactin. Research into Ipamorelin has examined whether it can stimulate growth hormone release with greater selectivity and fewer effects on these other hormonal pathways, though individual responses vary and a doctor assessment remains the appropriate way to evaluate suitability.
The rationale for combining CJC-1295 and Ipamorelin relates to their complementary mechanisms. CJC-1295 works through the GHRH receptor to signal the pituitary to produce growth hormone. Ipamorelin works through the ghrelin receptor to independently stimulate growth hormone release. Because they act on different receptors through different pathways, research has examined whether using them together produces a more pronounced effect on growth hormone signalling than either compound alone.
Important context: The combination of CJC-1295 and Ipamorelin is one of the more commonly discussed pairings in peptide research and clinical contexts. However, the appropriateness of any protocol, including whether a combination approach is suitable, is determined by a prescribing doctor based on an individual's health history and goals - not something that should be self-directed based on online information.
Research into CJC-1295 and Ipamorelin individually and in combination has examined their interaction with growth hormone pathways and the downstream effects that growth hormone influences in the body. These include areas related to body composition, recovery processes, sleep quality and metabolic function. Much of the research, particularly regarding their use in combination, has been conducted in animal models or small clinical studies. The evidence for specific outcomes in diverse human populations is less developed than the volume of online discussion might suggest.
Because CJC-1295 influences growth hormone and IGF-1 pathways, protocols involving this compound typically require blood testing. This allows the prescribing doctor to monitor how an individual is responding and make informed decisions about whether continuation is appropriate. This monitoring requirement is one of the things that distinguishes properly supervised protocols from unregulated self-directed use.
Both compounds are Schedule 4 prescription-only medicines. They are legal to access when prescribed by an AHPRA-registered medical practitioner following a clinical assessment, and dispensed through a licensed compounding pharmacy. They cannot be legally purchased without a prescription, imported for personal use without proper authorisation, or sourced from unregulated online channels.